

ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Nov 7, 2021




RESPIRATORY PATHOGEN PANEL Nov 7, 2021 Positivity Rate (%)

MONTH	FLU A Total	FLU A (H1N1)	2009 (H1N1)	FLU A (H3N2)	FLU B	RSV A	RSV B	RSV Total	PARA 1	PARA 2	PARA 3	PARA 4	Corona 229E	Corona NL63	Corona OC43	Corona HKU1	Meta pneumo	Entero Rhino	ADENO	BOCA	Legio nella	Chla mydia	Myco plasma	
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0	
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0	
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1	
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0	
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1	
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1	
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0	
AUG	0.0	0.0	0.0	0.0	0.0	0.8	12.5	13.3	0.0	1.2	6.2	0.1	0.1	0.1	0.5	0.0	0.7	14.0	1.3	3.6	0.0	0.0	0.0	
SEP	0.0	0.0	0.0	0.0	0.0	0.7	10.6	11.3	0.0	0.9	1.8	0.4	0.0	0.0	0.4	0.0	0.6	23.6	0.8	4.1	0.1	0.0	0.1	
OCT	0.0	0.0	0.0	0.0	0.0	0.5	7.3	7.8	0.0	1.6	1.2	1.0	0.1	0.0	0.4	0.0	0.3	21.0	1.2	4.0	0.2	0.0	0.0	
NOV	0.0	0.0	0.0	0.0	0.0	0.0	8.8	8.8	0.0	2.6	1.6	1.6	0.0	0.0	0.0	0.0	0.7	19.9	0.7	2.6	0.0	0.0	0.0	
DEC																								



Increased prevalence of viruses: **Rhinovirus, RSV and Boca virus**

ACL RSVAG and PCR - Pos rate (%) - Nov 7, 2021



ACL RSV positivity rate - trends down

CDC Data RSV pos rate for Region 5 Chicago - (PCR – 16%↓, Antigen - 20% ↓)




CDC RSV positivity rate - trends down

SARS-COV-2					Influenza - no activity				RSV (Antigen+PCR)				Hologic Aptima	
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR	IL % COV19	WI % COV19
Nov 7	3.8	7.4	6.6	17.6	0	0.3	n/a	0	n/a	25.0	21.4	27.7	3.2	7.8
Oct 31	3.8	6.3	4.8	13.7	0.3	0	n/a	0	18.5	25.0	20.9	32.2	1.9	7.1
Oct 24	3.7	5.6	5.1	16.7	0	0.2	n/a	0	19.0	29.3	22.5	30.6	2.2	7.0
Oct 17	3.7	6.5	7.0	18.0	0	0	0	0	20.0	36.0	27.0	31.3	2.8	9.1
Oct 10	4.3	7.6	5.0	18.2	0	0.2	0	0	22.2	31.8	23.9	32.6	2.2	9.7
Oct 3	5.0	8.6	6.0	16.6	0	0	0	0	20.0	34.0	24.9	35.5	3.0	9.8
Sep 26	5.0	8.1	4.4	15.2	0	0	0	0	27.7	35.9	30.0	37.7	3.5	9.6
Sep 18	4.9	9.0	7.2	17.5	0	0	0	0	33.0	31.0	28.0	39.6	3.6	9.4
Sep 12	6.5	9.6	5.9	20.5	0	0	0	0	20.0	21.9	41.6	43.7	4.2	9.1
Sep 5	6.2	8.3	7.0	22.4	0	0	0	0	33.3	43.9	38.1	40.5	3.9	9.8
Aug 29	7.5	8.5	9.0	21.3	0	0	0	0	38.9	32.5	43.9	38.8	4.7	8.6


ACL RSV tests results are consistent with RSV outbreak

ACL COVAG and SCVPCR - Pos rate (%) - Nov 7, 2021




ACL Covid positivity rate - trends up

Nov 3, 2021 - daily COVID-19 cases in US - CDC



CDC Covid positivity rate - trends up

Nov 6, 2021 – SARS-CoV-2 circulating in the US (~99.6% % Delta variants)



US vaccination status CDC | Data as of: Nov 4, 2021

426,728,092

Vaccines Administered

222,591,394

People who received at least one dose

193,227,813


People who are fully vaccinated*

67.0%

Percentage of the US population that has received at least one dose


58.2%

Percentage of the US population that has been fully vaccinated*




ACL Flu positivity rate – no activity (2 pos out 1072 samples tested)

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 23, 2021 – October 30, 2021





CDC Midwest data as of: Oct 30, 2021




2021-22 Influenza Season Week 43 ending Oct 30, 2021

ILI Activity Level




CSF targets positivity rate is 3.1%

ACL RMEPNL - CSF POSITIVE TARGETS - Nov 7, 2021



The most prevalent GI bacterial target is - (Campy and Giardia)



The most prevalent GI viral target is – (Adeno – 0.6%)

ACL GPP - STOOL POSITIVE VIRAL TARGETS - Oct 31, 2021

